AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21538146 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 135
Study 19811710 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 2% diltiazem hydrochloride, applied perianally twice daily for 8 weeks
Number of subjects: 80
Study 19811710 — intervention group
Group type: COMPARATOR
Intervention: 0.2% glyceryl trinitrate (GTN), applied perianally twice daily for 8 weeks
Number of subjects: 80
Study 17311574 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone hydrogel lenses
Number of subjects: 30
Study 17311574 — intervention group
Group type: COMPARATOR
Intervention: Hydrogel lenses
Number of subjects: 30
Study 15079108 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic colloid solution (250 ml of 7.2% NaCl/6% Hydroxyethylstarch)
Number of subjects: 30
Study 15079108 — intervention group
Group type: COMPARATOR
Intervention: Usual Ringer solution (control group)
Number of subjects: 30
Study 11679441 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of nitroglycerin (GTN) at 1 microg.kg(‐1).min(‐1) for 4 hours
Number of subjects: 40
Study 11679441 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline infusion
Number of subjects: 40
Study 9018621 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubulization (11 cases)
Number of subjects: 18
Study 9018621 — intervention group
Group type: COMPARATOR
Intervention: Conventional microsurgical repair (7 cases)
Number of subjects: 18
Study 7524141 — intervention group
Group type: EXPERIMENTAL
Intervention: alfuzosin 2.5 mg TID
Number of subjects: 205
Study 7524141 — intervention group
Group type: COMPARATOR
Intervention: placebo TID
Number of subjects: 205
Study 30113638 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment 1 mg/m2/d (≈0.035 mg/kg/d)
Number of subjects: 0
Study 27068672 — intervention group
Group type: EXPERIMENTAL
Intervention: New amino acid-based formula (NAAF)
Number of subjects: 46
Study 27068672 — intervention group
Group type: COMPARATOR
Intervention: Commercial amino acid-based formula (AAF)
Number of subjects: 46
Study 23963307 — intervention group
Group type: EXPERIMENTAL
Intervention: Drospirenone 0.25 mg/17β‐estradiol 0.5 mg
Number of subjects: 735
Study 23963307 — intervention group
Group type: EXPERIMENTAL
Intervention: Drospirenone 0.5 mg/17β‐estradiol 0.5 mg
Number of subjects: 735
Study 23963307 — intervention group
Group type: EXPERIMENTAL
Intervention: 17β‐estradiol 0.3 mg
Number of subjects: 735
Study 23963307 — intervention group
Group type: EXPERIMENTAL
Intervention: Drospirenone/17β‐estradiol combinations
Number of subjects: 735
Study 23963307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 735
Study 23963307 — intervention group
Group type: EXPERIMENTAL
Intervention: Drospirenone/17β‐estradiol
Number of subjects: 735
Study 23963307 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatments
Number of subjects: 735
Study 22644587 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisystemic therapy (MST)
Number of subjects: 146
Study 22644587 — intervention group
Group type: COMPARATOR
Intervention: Telephone support
Number of subjects: 146
Study 20973952 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg
Number of subjects: 102
Study 20973952 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg
Number of subjects: 102
Study 20973952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 18952561 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 courses of anthracycline-based chemotherapy followed by 4 courses of docetaxel or paclitaxel in combination with trastuzumab, followed by 14 additional courses of trastuzumab (total of 18 doses)
Number of subjects: 2500
Study 18952561 — intervention group
Group type: COMPARATOR
Intervention: 3 courses of 3-weekly docetaxel in combination with weekly trastuzumab (total of 9 doses) followed by 3 courses of 5-fluorouracil/epirubicin/cyclophosphamide
Number of subjects: 2500
Study 17160151 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy
Number of subjects: 0
Study 12803277 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed messages
Number of subjects: 401
Study 12803277 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed messages
Number of subjects: 401
Study 10861325 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacille Calmette‐Guérin vaccine
Number of subjects: 13
Study 10861325 — intervention group
Group type: COMPARATOR
Intervention: Case-control studies
Number of subjects: 13
Study 8971495 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphocreatine (PCr) administration
Number of subjects: 8
Study 8971495 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isotonic NaCl solution)
Number of subjects: 8
Study 1482151 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin plus amikacin
Number of subjects: 170
Study 1482151 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime plus amikacin
Number of subjects: 170
Study 1482151 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin plus amikacin with vancomycin
Number of subjects: 170
Study 1482151 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime plus amikacin with vancomycin
Number of subjects: 170
Study 4051146 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocromil
Number of subjects: 10
Study 4051146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30444137 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (switch group)
Number of subjects: 85
Study 30444137 — intervention group
Group type: COMPARATOR
Intervention: Continue same ARB (continue group)
Number of subjects: 85
Study 30352784 — intervention group
Group type: EXPERIMENTAL
Intervention: Selinexor (60, 80, or 100 mg orally) plus bortezomib (1.3 mg/m2 subcutaneously) and dexamethasone (20 mg orally) once or twice weekly in 21- or 35-day cycles.
Number of subjects: 42
Study 30352784 — intervention group
Group type: EXPERIMENTAL
Intervention: Selinexor (100 mg once weekly), bortezomib (1.3 mg/m2 once weekly for 4 weeks), and dexamethasone (40 mg once weekly) per 35-day cycle (recommended phase 2 dose).
Number of subjects: 42
Study 30352784 — intervention group
Group type: EXPERIMENTAL
Intervention: Selinexor plus bortezomib and dexamethasone (SVd).
Number of subjects: 42
Study 27247261 — intervention group
Group type: EXPERIMENTAL
Intervention: so-tDCS (0.75 Hz; max. current density 0.522 mA/cm²)
Number of subjects: 21
Study 27247261 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 21
Study 25263038 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal toric intraocular lens (IOL) implantation
Number of subjects: 30
Study 25263038 — intervention group
Group type: COMPARATOR
Intervention: Nontoric multifocal IOL combined with peripheral corneal relaxing incisions (PCRIs)
Number of subjects: 30
Study 22919238 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal indomethacin administered immediately after ERCP
Number of subjects: 0
Study 22919238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20652391 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic UV photo/photoaging intervention
Number of subjects: 126
Study 20652391 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention plus downward social comparison
Number of subjects: 126
Study 20652391 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention plus upward social comparison
Number of subjects: 126
Study 20652391 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 126
Study 17604800 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous myoblasts and fibroblasts
Number of subjects: 63
Study 17604800 — intervention group
Group type: COMPARATOR
Intervention: Collagen
Number of subjects: 63
Study 16137981 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced sulphurous mineral water baths
Number of subjects: 60
Study 16137981 — intervention group
Group type: COMPARATOR
Intervention: Modified tap water baths
Number of subjects: 60
Study 12214938 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether (1.6 mg/kg body wt., repeated after 12 hrs and then daily for four days)
Number of subjects: 77
Study 12214938 — intervention group
Group type: COMPARATOR
Intervention: Quinine (10 mg/kg body wt in 10 ml/kg body wt of 5% dextrose in 0.9% saline intravenously, repeated every 8 hrs and changed to oral administration when the child was able to drink to finish seven days)
Number of subjects: 77
Study 9862595 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-octylcyanoacrylate
Number of subjects: 124
Study 9862595 — intervention group
Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 124
Study 8588960 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cefadroxil
Number of subjects: 559
Study 8588960 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cefuroxime
Number of subjects: 559
Study 2633082 — intervention group
Group type: EXPERIMENTAL
Intervention: CP-enriched cardioplegia at a concentration of 10 mmol/l
Number of subjects: 40
Study 2633082 — intervention group
Group type: COMPARATOR
Intervention: Plain cardioplegia
Number of subjects: 40
Study 876671 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal group with personal control instructions
Number of subjects: 50
Study 876671 — intervention group
Group type: EXPERIMENTAL
Intervention: External group with environmental control instructions
Number of subjects: 50
Study 876671 — intervention group
Group type: COMPARATOR
Intervention: Models who were tolerant, intolerant, or inactive
Number of subjects: 50
Study 876671 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent disclosure of the model's roles
Number of subjects: 50
Study 29915994 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Thinking Group (PTC)
Number of subjects: 90
Study 29915994 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Regulation Condition (SRC)
Number of subjects: 90
Study 29915994 — intervention group
Group type: COMPARATOR
Intervention: Cancer-Fact Group (CFC)
Number of subjects: 90
Study 28571019 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Flux Hemodialysis (HD)
Number of subjects: 0
Study 25581584 — intervention group
Group type: EXPERIMENTAL
Intervention: MAL-PDT
Number of subjects: 601
Study 25581584 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod cream
Number of subjects: 601
Study 25581584 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil cream
Number of subjects: 601
Study 23484178 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio‐Oss
Number of subjects: 10
Study 23484178 — intervention group
Group type: EXPERIMENTAL
Intervention: NanoBone
Number of subjects: 10
Study 23484178 — intervention group
Group type: COMPARATOR
Intervention: Control (no filling)
Number of subjects: 10
Study 21372734 — intervention group
Group type: EXPERIMENTAL
Intervention: High level of social support
Number of subjects: 333
Study 19462697 — intervention group
Group type: EXPERIMENTAL
Intervention: Kansas City Cardiomyopathy Questionnaire (KCCQ) summary score
Number of subjects: 0
Study 19462697 — intervention group
Group type: EXPERIMENTAL
Intervention: Not good QoL (< 75) in NYHA II patients
Number of subjects: 0
Study 19462697 — intervention group
Group type: EXPERIMENTAL
Intervention: KCCQ summary scores
Number of subjects: 0
Study 17941858 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (up to 105 mg/day)
Number of subjects: 6
Study 17941858 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (over 90 mg/day)
Number of subjects: 6
Study 15001200 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil/HCTZ 20/12.5 mg
Number of subjects: 502
Study 15001200 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil/HCTZ 40/25 mg
Number of subjects: 502
Study 15001200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 502
Study 11737935 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant administration
Number of subjects: 0
Study 11737935 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 9787943 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) at a dose of 2 g/d
Number of subjects: 133
Study 9787943 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 133
Study 9787943 — intervention group
Group type: COMPARATOR
Intervention: Control group (CMV disease-free patients)
Number of subjects: 133
Study 8011800 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (30 mg orally)
Number of subjects: 73
Study 2475681 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release verapamil (240-mg tablets), given once or twice daily
Number of subjects: 14
Study 2475681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 2475681 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release verapamil
Number of subjects: 14
Study 367715 — intervention group
Group type: EXPERIMENTAL
Intervention: Syndol (analgesic combination)
Number of subjects: 12
Study 367715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 28668970 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC) for 2 weeks, 6 hours daily bilateral calf IPC applied under an orthosis on the injured side.
Number of subjects: 150
Study 28668970 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (plaster cast without IPC) for 2 weeks.
Number of subjects: 150
Study 26930156 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe PE/GH
Number of subjects: 4323
Study 26930156 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild PE/GH
Number of subjects: 4323
Study 26930156 — intervention group
Group type: COMPARATOR
Intervention: Normotensive women
Number of subjects: 4323
Study 23937924 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeon delivered psoas compartment block
Number of subjects: 53
Study 23937924 — intervention group
Group type: COMPARATOR
Intervention: Control group (no psoas compartment block)
Number of subjects: 53
Study 21775876 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice daily
Number of subjects: 2532
Study 21775876 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium 220 mg twice daily
Number of subjects: 2532
Study 21775876 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2532
Study 21520659 — intervention group
Group type: EXPERIMENTAL
Intervention: Ileo colic intubation
Number of subjects: 40
Study 21520659 — intervention group
Group type: COMPARATOR
Intervention: Resection anastomosis
Number of subjects: 40
Study 21520659 — intervention group
Group type: COMPARATOR
Intervention: Ileostomy
Number of subjects: 40
Study 18946890 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide with valsartan
Number of subjects: 9518
Study 18946890 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide with valsartan-placebo
Number of subjects: 9518
Study 18946890 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide-placebo with valsartan
Number of subjects: 9518
Study 18946890 — intervention group
Group type: COMPARATOR
Intervention: Nateglinide-placebo with valsartan-placebo
Number of subjects: 9518
Study 15978968 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal salmon calcitonin (200 IU/day)
Number of subjects: 50
Study 15978968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 11840366 — intervention group
Group type: COMPARATOR
Intervention: Synthetically modified cellulosic (SMC) membrane after 3 months
Number of subjects: 18
Study 11840366 — intervention group
Group type: COMPARATOR
Intervention: Synthetically modified cellulosic (SMC) membrane after 6 months
Number of subjects: 18
Study 11840366 — intervention group
Group type: COMPARATOR
Intervention: Cellulose diacetate (CD) membrane after 3 months
Number of subjects: 18
Study 11840366 — intervention group
Group type: COMPARATOR
Intervention: Cellulose diacetate (CD) membrane after 6 months
Number of subjects: 18
Study 10386278 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg
Number of subjects: 45
Study 10386278 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine 1 to 1.5 mg/kg
Number of subjects: 45
Study 10386278 — intervention group
Group type: COMPARATOR
Intervention: Atracurium 0.5 mg/kg
Number of subjects: 45
Study 9038563 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac
Number of subjects: 18
Study 9038563 — intervention group
Group type: COMPARATOR
Intervention: Calcium and calciferol
Number of subjects: 18
Study 1763654 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (300 micrograms daily)
Number of subjects: 25
Study 1763654 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocryptine (5 mg daily)
Number of subjects: 25
Study 6353478 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamidol 370
Number of subjects: 0
Study 6353478 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamidol 300
Number of subjects: 0
Study 6353478 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher concentration of non-ionic contrast media
Number of subjects: 0
Study 6353478 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ionic contrast media
Number of subjects: 0
Study 30967104 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy dietary pattern adherence
Number of subjects: 96
Study 30967104 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant therapy
Number of subjects: 96
Study 30967104 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalization of body weight
Number of subjects: 96
Study 30967104 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 96
Study 31581789 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 13885
Study 31581789 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 13885
Study 31581789 — intervention group
Group type: COMPARATOR
Intervention: Control (Clopidogrel)
Number of subjects: 13885
Study 31581789 — intervention group
Group type: EXPERIMENTAL
Intervention: All procedures (peripheral revascularization, coronary revascularization, lower extremity amputation)
Number of subjects: 13885
Study 26637841 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD + ASD (n=93)
Number of subjects: 392
Study 26637841 — intervention group
Group type: COMPARATOR
Intervention: ADHD (n=299)
Number of subjects: 392
Study 26607249 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitrite (80 or 160 mg/day, capsules, TheraVasc)
Number of subjects: 0
Study 24412929 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glulisine (GLU)
Number of subjects: 56
Study 24412929 — intervention group
Group type: COMPARATOR
Intervention: Insulin aspart (ASP)
Number of subjects: 56
Study 22240636 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate seed oil (PGS) 30 mg, 127 μg of steroidal phytoestrogens per dose, taken twice daily for 12 weeks
Number of subjects: 81
Study 22240636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 22240636 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate seed oil (PGS)
Number of subjects: 81
Study 19925608 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation protection cabin
Number of subjects: 60
Study 19925608 — intervention group
Group type: COMPARATOR
Intervention: Standard protection with a 0.5 mm lead-equivalent apron (control)
Number of subjects: 60
Study 18575579 — intervention group
Group type: EXPERIMENTAL
Intervention: D3 receptor‐preferring agonist pramipexole
Number of subjects: 0
Study 18575579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15851283 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD pacemaker implantation
Number of subjects: 48
Study 12403400 — intervention group
Group type: EXPERIMENTAL
Intervention: Short dialysis (150 minutes)
Number of subjects: 14
Study 12403400 — intervention group
Group type: COMPARATOR
Intervention: Long dialysis (240 minutes)
Number of subjects: 14
Study 10454450 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA (4 g/d)
Number of subjects: 59
Study 10454450 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA (4 g/d)
Number of subjects: 59
Study 10454450 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (placebo)
Number of subjects: 59
Study 8634157 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.234% NaF/silica/10% xylitol dentifrice
Number of subjects: 2630
Study 8634157 — intervention group
Group type: COMPARATOR
Intervention: 0.243% NaF/silica dentifrice (positive control)
Number of subjects: 2630
Study 2185155 — intervention group
Group type: EXPERIMENTAL
Intervention: Clavulanate‐potentiated amoxicillin (Augmentin)
Number of subjects: 141
Study 2185155 — intervention group
Group type: COMPARATOR
Intervention: Fosfomycin trometamol
Number of subjects: 141
Study 7466380 — intervention group
Group type: EXPERIMENTAL
Intervention: Active hemodialysis
Number of subjects: 8
Study 7466380 — intervention group
Group type: COMPARATOR
Intervention: Sham dialysis
Number of subjects: 8
Study 30303832 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 0
Study 30303832 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 0
Study 28150431 — intervention group
Group type: EXPERIMENTAL
Intervention: Terminally branching scheme
Number of subjects: 86
Study 28150431 — intervention group
Group type: COMPARATOR
Intervention: Hybrid scheme
Number of subjects: 86
Study 26558386 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation combined with constraint-induced movement therapy
Number of subjects: 20
Study 26558386 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation with constraint-induced movement therapy
Number of subjects: 20
Study 26558386 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Number of subjects: 20
Study 26558386 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation and CIMT
Number of subjects: 20
Study 26558386 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroimaging
Number of subjects: 20
Study 26558386 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation techniques
Number of subjects: 20
Study 23897942 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine-epinephrine-tetracaine
Number of subjects: 221
Study 23897942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study 21252503 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemofiltration (HF)
Number of subjects: 34